BusinessCue Biopharma Shares Surge 41.6% After Positive Phase 2 Trial Results
Cue Biopharma's shares jumped 41.6% in premarket trading following the announcement of positive topline results from a Phase 2 clinical trial. The trial evaluated the efficacy of their treatment, leading to increased investor confidence and a significant stock price rise. This development marks a key milestone for the company in advancing its clinical pipeline.
Yahoo! News·




